About Dulaglutide
Class: GLP-1 RA (weekly)
Brand/Manufacturer: Generic / Trulicity
Dosing: Weekly subcutaneous
Mean weight loss: 4-5%
Pivotal trial: AWARD, REWIND
Dulaglutide (Trulicity) is a once-weekly GLP-1 RA approved for type 2 diabetes only. Modest weight loss compared to semaglutide and tirzepatide. Cardiovascular outcome benefit established in REWIND (T2D with high CV risk).
Mechanism of action
Dulaglutide acts on the GLP-1 receptor (and GIP receptor in the case of tirzepatide), producing four primary effects: central appetite suppression, delayed gastric emptying, glucose-dependent insulin release, and glucagon suppression. The combined effect on body weight averaged across pivotal trials is 4-5% body weight reduction at the trial endpoint.
Clinical evidence
The pivotal trial supporting Dulaglutide's weight management indication is AWARD, REWIND. Detailed data including primary and secondary endpoints, population characteristics, and adverse event frequencies is summarized on our clinical research page.
How to access Dulaglutide via telehealth
Dulaglutide is available through several U.S. telehealth providers. Compounded versions (where applicable) are dispensed by 503A licensed compounding pharmacies and 503B FDA-registered outsourcing facilities. NexLife is our editorial #1 pick for Dulaglutide access — see the side panel for details.
FAQ
Is Dulaglutide FDA-approved?
The brand-name versions of Dulaglutide are FDA-approved for the indications listed above. Compounded versions are not FDA-approved.
How much does Dulaglutide cost?
Brand-name Dulaglutide typically costs hundreds to over a thousand dollars per month at retail. Compounded equivalents (where available) cost significantly less. See our cost guide for verified May 2026 pricing.